造影剂肾病防治的研究进展  

Advances in Prevention of Contrast-induced Nephropathy

作　　者：高照[1] 黄奕君[1] 许晋川[1] GAO Zhao;HUANG Yijun;XU Jinchuan(Hainan Provincial People＇s Hospital,Haikou 570311,Hainan,China)

机构地区：[1]海南省人民医院,海南海口570311

出　　处：《心血管病学进展》2018年第3期501-505,共5页Advances in Cardiovascular Diseases

摘　　要：随着人口的老龄化、心血管疾病的流行以及碘造影剂相关诊疗技术的普及,罹患造影剂肾病的高危人群不断扩大,而造影剂肾病是肾功能急剧恶化和预后不良的标志事件。过去十年,虽然人们对造影剂诱导的急性肾损伤的早期诊断、风险分层和防治进行了大量研究,并取得一些进展,但在现实世界的临床获益仍不尽人意。现对当前造影剂肾病防治的研究进展进行综述,拟为进一步深入研究新的干预措施奠定基础。With an increasingly aging population,the prevalence of cardiovascular diseases and growing use of general iodinated contrast-elated medical practices, the number of patients susceptible to contrast-induced nephropathy（CIN） cintinues to rise. The occurrence of CIN is a turning-point in rapidly deteriorating renal function and poor prognosis. Although over the last decade, considerable progress hasbeen made in the early diagnosis, the risk stratification and prevention of contrast-induced acute kidney injury, clinical benefits in the real world remain unsatisfactory. Therefore,the current advances in prevention of CIN were reviewed in this article in order to guide the further research on better intervention.

关 键 词：造影剂肾病 造影剂 急性肾损伤 氧化应激 炎症 

分 类 号：R54[医药卫生—心血管疾病]